Lenalidomide Teva

Lenalidomide, the active ingredient in Lenalidomide Teva, is an immunomodulatory drug (IMiD) presented as an oral formulation for oral use. It is employed in the treatment of certain hematologic malignancies, including multiple myeloma, myelodysplastic syndromes, and mantle cell lymphoma, in adult patients.

GNH USA supplies Lenalidomide Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and clinical use globally.

Lenalidomide is an immunomodulatory agent used in hematologic malignancies. - Multiple myeloma: improves progression‑free survival and overall response rates in adult patients. - Myelodysplastic syndromes: reduces transfusion dependence and may modify disease course in patients with del(5q) cytogenetic abnormality. - Mantle cell lymphoma: contributes to disease control when combined with other therapies in relapsed or refractory cases.

Lenalidomide may cause a range of adverse reactions, varying in frequency and severity. Common Side Effects: - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: low platelet levels that may cause bleeding. - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may lead to dehydration. - Rash: mild skin eruptions. - Nausea: mild to moderate nausea often occurring early in therapy. - Constipation: difficulty passing stools that may require laxatives. Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism requiring immediate attention. - Severe neutropenia: profound drop in neutrophils leading to febrile neutropenia. - Hepatotoxicity: elevated liver enzymes or liver injury. - Secondary primary malignancies: emergence of new cancers during treatment. - Hypersensitivity reactions: severe skin rash, Stevens‑Johnson syndrome, or anaphylaxis requiring urgent care.

When prescribing Lenalidomide, clinicians should observe several precautionary measures to minimize risks. - Pregnancy contraindication: teratogenic (Category X); avoid use and ensure effective contraception. - Thromboembolic risk: evaluate need for prophylactic anticoagulation in at‑risk patients. - Renal impairment: consider dose reduction in patients with decreased kidney function. - Hepatic dysfunction: monitor liver enzymes and adjust therapy if significant abnormalities arise. - Infection monitoring: watch for fever or infection signs due to neutropenia and advise prompt reporting. - Store at ambient temperature: keep below 25 °C in original container, protect from moisture and light.

Lenalidomide may interact with several medicines, influencing efficacy or safety. Major Interactions (Avoid): - Strong CYP3A4 inducers: agents such as rifampin markedly reduce lenalidomide exposure. - Anticoagulants: concurrent use can increase bleeding risk; monitor INR or adjust dose. - Immunosuppressants: may diminish therapeutic effect; careful assessment required. - Teratogenic agents: co‑administration with other known teratogens should be avoided. Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors: ketoconazole or clarithromycin can raise plasma levels modestly. - P-glycoprotein substrates: digoxin levels may be affected; monitor concentrations. - Vaccines: live attenuated vaccines should be avoided due to immunomodulation. - NSAIDs: may increase risk of renal toxicity when combined with lenalidomide. - Diuretics: may increase risk of dehydration and electrolyte imbalance; monitor patient status.